Phospho-dependent Regulation of SAMHD1 Oligomerisation Couples Catalysis and Restriction. by Arnold, Laurence H et al.
RESEARCH ARTICLE
Phospho-dependent Regulation of SAMHD1
Oligomerisation Couples Catalysis and
Restriction
Laurence H. Arnold1☯, Harriet C. T. Groom1☯, Simone Kunzelmann1, David Schwefel1,
Sarah J. Caswell1, Paula Ordonez1, Melanie C. Mann1, Sabrina Rueschenbaum1, David
C. Goldstone1¤, Simon Pennell1, Steven A. Howell1, Jonathan P. Stoye1,2, Michelle Webb3,
Ian A. Taylor1*, Kate N. Bishop1*
1 The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, Mill Hill, London, United Kingdom,
2 Faculty of Medicine, Imperial College London, London, United Kingdom, 3 Centre for Genomic Medicine,
Institute for Human Development, Faculty of Medicine and Human Sciences, University of Manchester,
Manchester, United Kingdom
☯ These authors contributed equally to this work.
¤ Current address: School of Biological Sciences, University of Auckland, Auckland, New Zealand
* Ian.Taylor@crick.ac.uk (IAT); Kate.Bishop@crick.ac.uk (KNB)
Abstract
SAMHD1 restricts HIV-1 infection of myeloid-lineage and resting CD4+ T-cells. Most likely
this occurs through deoxynucleoside triphosphate triphosphohydrolase activity that reduces
cellular dNTP to a level where reverse transcriptase cannot function, although alternative
mechanisms have been proposed recently. Here, we present combined structural and viro-
logical data demonstrating that in addition to allosteric activation and triphosphohydrolase
activity, restriction correlates with the capacity of SAMHD1 to form “long-lived” enzymati-
cally competent tetramers. Tetramer disruption invariably abolishes restriction but has var-
ied effects on in vitro triphosphohydrolase activity. SAMHD1 phosphorylation also ablates
restriction and tetramer formation but without affecting triphosphohydrolase steady-state
kinetics. However phospho-SAMHD1 is unable to catalyse dNTP turnover under conditions
of nucleotide depletion. Based on our findings we propose a model for phosphorylation-
dependent regulation of SAMHD1 activity where dephosphorylation switches housekeeping
SAMHD1 found in cycling cells to a high-activity stable tetrameric form that depletes and
maintains low levels of dNTPs in differentiated cells.
Author Summary
SAMHD1 is a restriction factor that blocks infection of certain immune cells by HIV-1. It
was discovered to be an enzyme that catalyses the breakdown of dNTPs, suggesting that it
inhibits HIV-1 replication by reducing cellular dNTP pools to such low levels that reverse
transcriptase cannot function. However, recently, alternative mechanisms have been pro-
posed. SAMHD1 is also regulated by phosphorylation, although the effects of phosphory-
lation on protein function are unclear. In order to address these issues, we carried out
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combined structural and virological studies and have demonstrated that in addition to
allosteric activation and triphosphohydrolase activity, restriction correlates with the capac-
ity of SAMHD1 to form “long-lived” enzymatically competent tetramers. Disrupting the
tetramer in various ways always abolished restriction but had differing effects on enzyme
activity in vitro. SAMHD1 phosphorylation also prevented restriction and tetramer forma-
tion but without affecting enzyme catalysis under steady-state dNTP conditions. However
phosphorylated SAMHD1 was unable to catalyse dNTP turnover at very low nucleotide
levels that more accurately represent conditions in the cells in which restriction takes
place. Based on our findings we propose a model for phosphorylation-dependent regula-
tion of SAMHD1 activity and substantiate that degradation of dNTPs by SAMHD1 is suf-
ficient to restrict HIV-1.
Introduction
HIV-1 replicates poorly in cells of the myeloid lineage and resting T cells through blocks that
occur early in infection [1–3]. However, in HIV-2 and related simian viruses (SIVs) the lenti-
viral accessory protein Vpx overcomes this restriction by targeting the cellular protein
SAMHD1 for proteasomal degradation [4–6].
SAMHD1 is a GTP/dGTP-activated deoxynucleotide triphosphohydrolase [7]. It was first
identified through association with the rare genetic disorder Aicardi Goutières syndrome
(AGS), which mimics congenital viral infection [8]. Human SAMHD1 is a 626 amino acid pro-
tein comprising an N-terminal nuclear localisation signal [9], two major structural domains; a
sterile alpha motif (SAM) and an HD domain, together with CtD, a C-terminal region required
for interaction with Vpx isolated from SIV that infects sooty mangabey (SIVsmm) [10, 11].
SAM domains are present in a wide range of proteins and are generally involved in protein-
protein or protein-nucleic acid interactions [12]. The HD domain contains the active site of the
protein and in combination with N- and C-terminal sequences also incorporates the two allo-
steric nucleotide-binding sites, AL1 and AL2, that regulate the enzyme through combined
binding of G-based (AL1) and deoxynucleoside (AL2) triphosphates [7, 13, 14]. The CtD con-
tains the residues bound by SIVsmm Vpx that target human SAMHD1 to the ubiquitination
machinery and direct its subsequent proteasomal degradation [11].
SAMHD1 is proposed to suppress HIV-1 replication in restrictive cells by inhibiting reverse
transcription through depletion of the intracellular dNTP pool. This hypothesis is supported
by the inverse relationship between SAMHD1 levels and dNTP concentration (and conse-
quently HIV-1 infectivity) in a number of cell lines and primary cells [15–17]. However, there
is uncertainty as to the extent to which the different domains of SAMHD1 contribute to restric-
tion of HIV-1 infection. Some data suggest that only the HD domain is required for inhibition
of infection [18] and that removing the C-terminal region does not affect restriction [18, 19],
while other studies suggest that the SAM domain may influence function [20] and that the C-
terminal region is required for SAMHD1 activity in cells [21]. Although the HD domain has
consistently been found to be necessary for lentiviral restriction, some reports have questioned
whether this is due to its role in tetramerisation of the protein rather than the presence of the
catalytic site [18, 22]. Furthermore, SAMHD1 has been reported to have alternative nuclease
[20, 23] and/or RNA binding [24, 25] activities that, dependent on the cellular circumstances,
can also mediate restriction of HIV-1 [23]. In addition, restriction is regulated by Threonine
592 phosphorylation [19, 22, 26] and removing this regulation may enable SAMHD1 to inhibit
HIV-1 in cycling cells (Cribier et al., 2013).
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These latter observations question the role of triphosphohydrolase activity in restriction.
However, disparities in the field may be due to variation in assays used to determine enzyme
activity or could represent divergent strategies for retroviral restriction. Therefore, given these
controversies and the importance of SAMHD1 both as a potential therapeutic target and a key
intracellular regulator of metabolism, we set out to thoroughly investigate the activity and regu-
lation of SAMHD1 through a combined virological, structural and biochemical study of the
enzyme, both in cells and in vitro.
Results
SAMHD1 requires both a catalytic site and a C-terminal region for
restriction of HIV-1
To determine the regions of SAMHD1 required for restriction activity, a panel of SAMHD1
proteins comprising N- and C- terminal truncations as well as internal deletions was con-
structed (Fig 1A). The positions at which domains were defined were informed by structural
domain boundaries, as they would be more likely to generate stable and active proteins. Expres-
sion of each SAMHD1 deletion was assessed by western blotting and only mutants E and H
were expressed at lower levels than the full length protein suggesting that most constructs were
equally stable in cells (S1 Fig).
Each deletion mutant was assessed for its ability to restrict HIV-1 infection of differentiated
U937 cells using a single round, two-colour flow cytometry assay. In this assay, U937 cells were
first transduced with a bicistronic IRES vector expressing SAMHD1 and YFP and then differ-
entiated. Three days later, differentiated cells were challenged with HIV-1 virus-like particles
(VLP) expressing GFP, and after a further three days, the percentage of YFP-expressing cells
that were infected was measured by flow cytometry. As expected, mutants B and G, that did
not contain the HD domain, were unable to restrict HIV-1 infection similar to a catalytically
inactive mutant, 206-7AA (Fig 1B). However, not all mutants containing the HD domain were
able to restrict HIV-1 infection. For example, mutant A, containing only the HD domain, and
mutants C, D and F, containing the HD domain in combination with the NLS or SAM domains
or both respectively, did not restrict HIV-1 infection (Fig 1B, grey bars). Only mutants E, H
and I, containing both the HD domain and the C-terminal domain (CtD, residues 584–626),
inhibited infection (Fig 1B, red bars). Therefore, in agreement to previous observations [18, 21]
these data demonstrate that both the HD domain and the CtD are required for restriction but
that neither the NLS nor SAM domains are necessary. These results were substantiated in sta-
ble U937 lines expressing wild type SAMHD1 or mutants F or H (S2 Fig). Restriction by our
panel of deletion mutants was also tested in undifferentiated cycling U937 cells using a two-col-
our assay (Fig 1C). In agreement with previous reports, wild-type SAMHD1 was not able to
restrict HIV-1 replication in cycling cells. However, in contrast to a previous observation [19],
none of the deletion mutants, including those with a CtD deletion, were able to restrict replica-
tion in these cells either.
To test whether the SAM domain influenced the timing of the block to HIV-1 infection,
wild type SAMHD1 or domain mutants F (lacking the CtD) or H (lacking the SAM domain)
were introduced into U937 cells. Following differentiation and challenge with HIV-1 VLP, the
accumulation of reverse transcription products was measured by qPCR (Fig 1D). These data
show that wild-type SAMHD1 inhibits the accumulation of second strand reverse transcription
products by approximately 10-fold. Moreover, mutant H also inhibited the accumulation of
reverse transcripts to a similar degree, whereas the inactive mutant F did not affect reverse
transcription. Together, these data indicate that the SAM domain has no influence on the tim-
ing or the magnitude of the SAMHD1-mediated block to HIV-1 infection.
SAMHD1 Phosphorylation, Tetramers and Restriction
PLOS Pathogens | DOI:10.1371/journal.ppat.1005194 October 2, 2015 3 / 30
SAMHD1 Phosphorylation, Tetramers and Restriction
PLOS Pathogens | DOI:10.1371/journal.ppat.1005194 October 2, 2015 4 / 30
We also tested the ability of SAMHD1 to restrict a panel of HIV-1 VLP carrying mutations
in reverse transcriptase (RT) that reduce the affinity of the enzyme for dNTPs, and therefore
reduce RT processivity [27–29]. None of these mutations had a significant effect on viral infec-
tivity. However, all were found to be more sensitive to SAMHD1 restriction (Fig 1E), implying
that the affinity of RT for dNTPs correlates with restriction by SAMHD1. In addition, whilst
introduction of SAMHD1 in U937 cells substantially reduced the levels of cellular dNTPs,
mutant F, which lacks the CtD, did so but to a lesser extent (Fig 1F). This suggests that mutant
F has reduced triphosphohydrolase activity in cells, supporting the proposed correlation
between dNTP levels and restriction.
Oligomeric state and catalytic activity of SAMHD1(115–583)
Deletion of the CtD region of SAMHD1, residues 584–626, ablated its HIV-1 restriction activ-
ity in differentiated U937 cells. This region has been shown to promote tetramerisation of the
protein [13, 14, 21]. Therefore, to examine the effects of this truncation in vitro we compared
the solution oligomeric state of SAMHD1(115–626) and SAMHD1(115–583) following addi-
tion of substrates and allosteric regulators using Size Exclusion Chromatography coupled to
Multi-Angle Laser Light Scattering (SEC-MALLS). Addition of the allosteric regulator dGTP
to SAMHD1(115–626) resulted in formation of a ~225 kD species corresponding to a protein
tetramer (Fig 2A). In contrast, addition of dGTP to SAMHD1(115–583) failed to produce a tet-
rameric species that was stable under the conditions of the size exclusion chromatography (Fig
2A). Other G-based nucleotides, GTP or ddGTP, were insufficient to induce tetramerisation of
SAMHD1(115–626) (S3A Fig). However, when GTP was combined with dNTP substrates that
also act as AL2 activators [14, 30, 31], a varying amount of tetramer was formed, dependent on
the deoxynucleotide employed (S3B Fig). dATP and dGTP support the greatest degree of tetra-
mer formation, TTP is intermediate and dCTP appears to be ineffective. This same rank order
has also been reported for the AL2 dNTP binding preference based on the site occupancy of
crystal structures [30]. In addition, the GTP/dATP induced tetramer is highly stable (Fig 2B) as
even though more than 90% of the available dATP is hydrolysed to deoxyadenosine (dA) after
5 minutes incubation (Fig 2C), tetramers still persisted for up to 3 hours before the nucleotide-
free monomer-dimer equilibrium was re-established. These observations are consistent with
chemical crosslinking studies that showed SAMHD1 tetramers persist for hours after dilution
of activating nucleotides [31].
Having demonstrated that residues 584–626 are required for stable tetramer formation, a
comparison of the steady-state kinetics of dNTP hydrolysis by SAMHD1(115–626) and
Fig 1. Restriction activity of SAMHD1 deletion constructs. (A) Schematic of SAMHD1mutants showing the N-terminal domain in red with nuclear
localisation signal (NLS), the sterile alpha motif (SAM) domain in yellow, the HD domain in green and the C-terminal domain (CtD) in blue. Positions of
domain junctions along with active site point mutation residues are numbered above. The identifier (A–I) and amino acids present in each mutant are
indicated on the left. (B) Restriction of HIV-1 in differentiated cells. U937 cells were transduced with full-length SAMHD1, catalytically inactive SAMHD1
(HD206-7AA) or domain mutant VLPs co-expressing YFP. Cells were differentiated after three days and 72 hours later, infected with HIV-1GFP virus. The
bar graph shows the degree of restriction compared to SAMHD1 negative cells. Red bars highlight restriction competent SAMHD1. The black bar is the
negative control, SAMHD1(HD206-7AA). Error bars represent the range for n 8 independent experiments. (C) Restriction of HIV-1 in in cycling cells. U937
cells were transduced and infected as inB but without differentiation. The bar graph shows the degree of restriction with error bars representing the range for
n = 3 independent experiments. Red bars represent constructs that are able to restrict HIV-1 in differentiated U937 cells. (D) Inhibition of second-strand
reverse transcription products by SAMHD1. U937 cells were transduced with SAMHD1 or domain mutant SAMHD1, differentiated and infected with DNase-
treated HIV-1GFP. Cells were harvested at the indicated time points post-infection and second-strand reverse transcription products were detected by
qPCR. Graph shows a representative experiment (n 6). Error bars are the standard deviation within the qPCR replicate (E) SAMHD1 restriction of HIV-1
RT mutants. U937 cells were transduced with SAMHD1, differentiated as inB, and then infected with HIV-1GFP virus carrying the indicated mutations in RT.
The bar graph shows relative restriction compared to wild type (WT) HIV-1GFP. Error bars represent the range for n = 3 independent experiments. (F)
Analysis of cellular dNTP levels. U937 parental cells or cells stably expressing either full-length SAMHD1 or mutant F/ SAMHD(1–583) were differentiated by
adding PMA and 72 hours later dNTPs were extracted for quantification. The bar graph shows the relative amounts of each indicated dNTP in each cell line.
Error bars represent the range for n = 3 independent experiments.
doi:10.1371/journal.ppat.1005194.g001
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Fig 2. Solution oligomeric state and steady state kinetics of SAMHD1. (A) SEC-MALLS analysis of SAMHD1monomer-dimer-tetramer equilibrium for
SAMHD1(115–583) (red) and SAMHD1(115–626) (black). The chromatograms are the output from the differential refractometer. The points are the weight-
averaged molar masses determined at 1-second intervals throughout elution of chromatographic peaks. Dashed line chromatograms are apo-protein, solid
lines are upon addition of 0.5 mM dGTP (B) Tetramer stability. SAMHD1(115–626) was incubated with 0.1 mMGTP and 0.5 mM dATP for the specified time
intervals and then the oligomeric state analysed by SEC-MALLS. (C) Analysis of dATP hydrolysis during the time course shown inB. The chromatogram
(black) is the recorded UV absorbance at 260 nm from the SEC-MALLS column for the five-minute incubation time point. Reference chromatograms (dashed
lines) for substrate dATP (red) and product dA (blue) are overlaid. (D) Steady-state kinetic analysis of GTP stimulated hydrolysis of TTP by SAMHD1. The
dependence of the rate of on substrate concentration for SAMHD1(115–626) (black) and SAMHD1(115–583) (red) are plotted. Solid lines are the best fit to
the data using the Michaelis-Menten expression. Error bars represent the standard error of the mean (SEM) of three independent measurements. The
derived constants KM and kcat for the reaction are displayed inset.
doi:10.1371/journal.ppat.1005194.g002
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SAMHD1(115–583) was undertaken using quantitative real-time measurements of tripho-
sphohydrolase activity [32]. In these experiments, GTP was employed as an AL1 allosteric acti-
vator as it is not hydrolysed by SAMHD1 and TTP was used as both an AL2 allosteric activator
and a substrate. The concentration dependency of the enzyme rate was then fitted to a steady-
state Michaelis-Menten model, to derive the kinetic parameters. These data (Fig 2D), show that
both enzymes readily hydrolyse TTP, although SAMHD1(115–583) had ~ 10-fold reduced kcat
(0.15 sec-1 compared to 1.3 sec-1). Both enzymes had a similar KM (~90 μM) indicating that the
active site is competent and the affinity for substrate/transition state is unchanged. Therefore,
although stable tetramer formation is not a prerequisite for SAMHD1 catalysis under steady-
state conditions, it does support a higher turnover form of the enzyme and this appears neces-
sary for restriction.
SAMHD1 tetramer structures
To identify residues important for substrate binding, catalysis and tetramerisation we deter-
mined the co-crystal structures of SAMHD1(41–583) and SAMHD1(115–583) with the poorly
hydrolysable G-based nucleotide analogue, dideoxyguanosine triphosphate (ddGTP). Details
of the data collection, structure solution and refinement are presented in Table 1. SAMHD1
(41–583) contains the SAM domain however no electron density for the domain was observed,
suggesting a degree of flexibly in the linkage between the SAM and HD domain. The CtD is
absent in SAMHD1(41–583) and SAMHD1(115–583), and only the AL1 activator ddGTP is
present, nevertheless, although not stable under the conditions of our MALLS experiments,
both structures are tetrameric, made up from a dimer of dimers (Fig 3A). The primary dimer
interface is the same as that observed in other ligand-bound SAMHD1 tetramers [13, 14] and
in the apo-stucture [7]. However, the conformation of the tetramer differs, largely due to how
the α13 helices at the dimer-dimer interfaces pack against each other. The SAMHD1(41–583)
tetramer is symmetrical containing two equivalent dimer-dimer interfaces. In each interface,
interactions between R372, D361 and H364 form a hydrogen-bonding network along the
whole length of α13 (Figs 3B, left, and S4A). The same α13-mediated dimer-dimer interaction
is also observed in the SAMHD1(115–583) but in this case, only in one of the dimer-dimer
interfaces. In the second interface, only the first three N-terminal turns of α13 pack against
each other (Figs 3B, right, and S4A) and the side chain of D361 makes an alternative hydrogen
bonding interaction with R333 located on α12' of the opposing monomer. This non-equiva-
lence results in a SAMHD1(115–583) tetramer with an asymmetric arrangement and impor-
tantly also reveals that SAMHD1 tetramers have a degree of conformational flexibility.
SAMHD1 active sites
In SAMHD1(41–583) and SAMHD1(115–583) the active site contains bound ddGTP and sim-
ilar to previously described SAMHD1 structures [7, 13, 14], a tightly bound metal ion is co-
ordinated by the HD motifs (H167, D311 and H206, D207) and the triphosphate moiety of the
bound deoxynucleotide. However, comparison with other SAMHD1 tetramer structures crys-
tallised in the presence of a variety of metals [13, 14] reveals both differences in the nucleotide
position and also in the location of the metal centre (Figs 3C and S4B). Specifically, these differ-
ences affect how residues R164 and D207 interact with the triphosphate and also how the α, β
and γ phosphates of the nucleotide are positioned with respect to the metal ion. Given these
variations in active site configuration, the nature of the bound metal was examined by record-
ing anomalous diffraction data from a SAMHD1(115–583)-ddGTP crystal at the Fe absor-
bance edge and by measuring the X-ray fluorescence emission. Inspection of the anomalous-
difference electron density (S5A Fig) readily identifies a first series transition metal, attributed
SAMHD1 Phosphorylation, Tetramers and Restriction
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to Fe. However, the X-ray fluorescence emission spectrum (S5B Fig) contains peaks at the Zn
and Fe emission energies indicating the presence of both elements, findings also confirmed
using inductively coupled plasma mass spectrometry (ICP-MS) (S5C Fig). These data reveal
the presence of Fe and Zn, in a variety of different SAMHD1 constructs, albeit at varying ratio
but with a total stoichiometry of approximately 1:1 metal to protein indicating that both Zn
and Fe can occupy the active site. Taken together, these data demonstrate that the SAMHD1
active site can accommodate different metal ions and that the configuration of bound nucleo-
tides is dependent on the type of metal. Moreover, given that Zn is strongly inhibitory to












Wavelength (Å) 0.9795 1.735 0.92 0.9795 0.9795
Space group R32 P21 P21 P1 C2
Cell dimensions
a, b, c (Å) 163.2, 163.2, 260.7 70.1, 187.4, 81.4 69.7, 199.3, 81.8 81.9, 95.7, 97.6 197.55, 80.82, 147.66
α, β, γ (°) 90.0, 90.0, 120.0 90.0, 100.5, 90.0 90.0, 100.8, 90.0 91.4, 109.0, 115.3 90.0, 114.9, 90.0
Resolution (Å) 50.00 (3.96)–3.73 50.00 (2.70)–2.54 30.00 (3.14)-2.97 30.00 (3.18)-3.00 30.00 (3.92)-3.70
Rsym or Rmerge
(%)
17.0 (58.8) 7.6 (79.7) 11.5 (74.1) 5.8 (40.7) 10.8 (42.4)
I / σ(I) 12.23 (4.37) 17.96 (1.61) 13.06 (1.96) 10.52 (1.9) 9.76 (3.23)
Completeness
(%)
98.7 (92.5) 96.6 (80.0) 95.9 (81.3) 90.9 (83.1) 95.7 (92.8)
Redundancy 9.67 (8.26) 6.26 (4.12) 3.45 (3.13) 1.73 (1.69) 2.85 (2.75)
Reﬁnement
Resolution (Å) 50.00–3.73 50.00–2.54 30.00–2.97 30.00–3.00 50.00–3.7
No. reﬂections 13997 65181 43459 45128 22017
Rwork / Rfree 21.88 (26.77) 17.09 (22.01) 15.62 (23.44) 17.71 (24.73) 24.39 (30.82)
No. atoms
Protein 6785 14733 13993 14396 12094
Nucleotide 120 240 124 128 128
Ligand Fe 2 4 4 4 4
Ligand Mg 2 4 - - -
Ligand SO4 - 20 - 55 -
Water 3 170 4 5 -
B-factors
Protein 93.4 64.0 64.8 64.8 76.3
Nucleotide 96.2 81.3 85.4 109.9 52.9
Ligand Fe 60.9 45.4 62.9 32.7 50.0
Ligand Mg 79.3 82.2 - - -
Ligand SO4 - 140.7 - 119.4 -




0.006 0.011 0.011 0.01 0.005
Bond angles (°) 1.056 1.532 1.501 1.338 1.050
PDB Code 5ao0 5ao1 5a02 5ao3 5ao4
*Values in parentheses are for highest-resolution shell
doi:10.1371/journal.ppat.1005194.t001
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SAMHD1 triphosphohydrolase activity (S5D Fig) this supports the notion that differential
metal incorporation by SAMHD1 might be a means to regulate SAMHD1 activity and sub-
strate selectivity.
G-based nucleotides in the allosteric site
In the tetramer structures, as well as occupying the active site, ddGTP was also present at the
four allosteric AL1 sites, located at the conserved dimer interfaces. To ascertain if a differential
preference for G-based nucleotides in the allosteric site exists, two further structures were
determined, one with dGTP included in the crystallisation of an active site mutant SAMHD1
(115–583, R164A) and the other with GTP and the nucleotide analogue inhibitor 20,30-didehy-
dro-20,30-dideoxythymidine (d4T) included in the crystallisation of a SAMHD1(115–626) con-
struct. Details of the data collection, structure solution and refinement are presented in
Table 1. Both of these crystal forms also contain SAMHD1 tetramers. The SAMHD1(115–583,
R164A) structure has the same asymmetric conformation observed in the SAMHD1(115–
583)-ddGTP structure and has dGTP bound at the AL1 allosteric site. Nucleotides are absent
from the active site likely as a result of the introduction of the R164A substrate binding muta-
tion. SAMHD1(115–626) was crystallised in the presence of both GTP and d4T. The asymmet-
ric unit again comprises four SAMHD1(115–626) molecules arranged as two dimers but with
only a minimal contact between one pair of adjacent α13 helices. In this structure, GTP occu-
pies AL1 and again the active site is empty.
A comparison of the nucleotide configuration at the AL1 site for ddGTP, dGTP and GTP
bound structures is shown in Fig 4A. The electron density that nucleotides were built into is
presented in S6 Fig. The G base in all three structures makes the same hydrogen bonds with
D137, Q142 and R145 of one monomer along with a stacking interaction with R451' of the
opposing monomer. The basic side chains of K116 and R451' also make equivalent electrostatic
interactions with the triphosphate of the bound nucleotide illustrating that the binding mode
for each of the guanine nucleotides is broadly conserved. Therefore, the capacity of each G-
based nucleotide to support tetramerisation when combined with dATP was assessed using
SEC-MALLS (Fig 4B). These data show that all G-based nucleotides facilitate tetramer forma-
tion but to differing degrees in a rank order of GTP> dGTP> ddGTP. This supports the
notion that in a cellular context, where the concentration of GTP is greater than that of any
dNTP counterpart, tetramer formation is not limited by the availability of guanine-based
nucleotides to occupy AL1, but instead by the availability and capacity of dNTPs to produc-
tively support tetramer formation through occupancy of AL2.
Residues that mediate dNTP hydrolysis, allostery and tetramerisation,
are all required for SAMHD1 restriction activity
Based upon our observations in the crystal structures, amino acid substitutions were made to
disrupt key residues in the active site of the HD domain, the allosteric site and at the dimer-
Fig 3. Structures of SAMHD1 tetramers. (A) Crystal structures of SAMHD1(41–583) (left) and SAMHD1(115–583) (right) tetramers. Individual monomers
are coloured cyan, green, magenta and orange. Bound ddGTPmolecules in the active and allosteric sites are shown in yellow and green stick representation
respectively. Metal ions are shown as spheres. (B) The conserved dimer-dimer interface of SAMHD1(41–583) and SAMHD1(115–583) (left) and the non-
conserved SAMHD1(115–583) dimer-dimer interface (right). For clarity only two SAMHD1monomers, comprising one dimer-dimer interface are shown in
each panel. Active site bound ddGTP and residues that make interactions at the subunit interface are shown as sticks. Dashed lines represent hydrogen
bonding interactions. (C) A comparison of the bound nucleotide conformation and metal configuration of SAMHD1 tetramers is shown. Nucleotides are
shown in stick representation, metal ions as spheres: Fe (brown), Mn (purple), Mg (green) and Zn (blue). SAMHD1 residues that chelate metal ions and/or
triphosphate are labelled. (I) SAMHD1(41–583)-ddGTP, (II) SAMHD1(115–583)-ddGTP, (III) SAMHD1(113–626)-dGTPαS [13] (PDB ID 4BZC), (IV)
SAMHD1(113–626 HD206/207RN)-dGTP [13] (PDB ID 4BZB), (V) SAMHD1(109–626)-dGTP [14] (PDB ID 4MZ7).
doi:10.1371/journal.ppat.1005194.g003
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Fig 4. Different G based nucleotides can be accommodated in the SAMHD1 allosteric site. (A) The contents and conformation of the allosteric sites for
structures of SAMHD1(115–583)-ddGTP (top), SAMHD1(115–583[R164A])-dGTP (middle) and SAMHD1(115–626)-GTP (bottom) are shown. Nucleotides
are shown in stick representation, SAMHD1 residues making contacts with the nucleotides are labelled. (B) SEC-MALLS analysis of SAMHD1(115–626)
incubated with ddGTP/dATP(blue), dGTP/dATP (green) or GTP/dATP (orange). The chromatograms are the output from the differential refractometer. The
points are the weight-averaged molar masses determined at 1-second intervals throughout elution of chromatographic peaks.
doi:10.1371/journal.ppat.1005194.g004
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dimer interface. The SAMHD1 mutant proteins were then tested for inhibition of HIV-1 infec-
tion using the two-colour restriction assay (Fig 5). These data show that when residues that co-
Fig 5. Restriction by active site, allosteric site and tetramer mutants.U937 cells were transduced with the indicated SAMHD1 point mutations at (A) the
active site, (B) the allosteric site or (C) the tetramer interface. Cells were differentiated, infected and analysed as in Fig 1B. The bar charts show the fold
restriction. The error bars represent standard deviation of the mean (n3). (D) SEC-MALLS analysis of wild type SAMHD1(black) and SAMHD1(R372D)
(blue) incubated with 0.1 mMGTP and 0.5 mM dATP. The chromatograms are the output from the differential refractometer. The red points are the weight-
averaged molar masses determined for the two peaks in wt. SAMHD1. (E) Steady-state kinetic analysis of GTP stimulated hydrolysis of TTP, by SAMHD1
(black) and SAMHD1(R372D) (blue). The dependence of the rate of on substrate concentration is plotted. Error bars represent SEM of two independent
measurements. Solid lines are the best fit to the data using the Michaelis-Menten expression. The derived constants KM and kcat for wt. SAMHD1 are
displayed inset.
doi:10.1371/journal.ppat.1005194.g005
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ordinate the bound iron in the active site (H167, H206, D207 and D311) were replaced with
alanine, restriction activity was abolished, confirming that SAMHD1 metal co-ordination in
the active site is a requirement for restriction. In addition, alanine substitution of residues that
make hydrogen bonds with the phosphates of the bound nucleotide (R164, H233, K321 and
Y315) also abolished restriction activity highlighting the necessity for dNTP substrate binding
for restriction activity (Fig 5A). Further alanine substitutions were introduced at allosteric site
residues R143 and R145 that are mutated in AGS patients [8]. R145 is involved in guanine base
recognition and R143 projects from the allosteric site to the rear of the active site. These alanine
mutations also abolished SAMHD1 restriction activity (Fig 5B), demonstrating that allosteric
activation of SAMHD1 is a further requirement for restriction.
Residue R372 is located at dimer-dimer interface of the tetramer structures and contributes
substantially to the hydrogen-bonding network between the adjacent α13 helices (Fig 3B).
Therefore, we examined the effects of a charge reversal mutation, R372D, on SAMHD1 restric-
tion and found that this abolished restriction activity (Fig 5C). Moreover, the R372D mutation
completely removed the ability of SAMHD1 to form tetramers (Fig 5D) and resulted in a loss
of SAMHD1 in vitro triphosphohydrolase activity (Fig 5E) supporting the notion that
SAMHD1 tetramerisation mediated through allosteric activation is a requirement for both
SAMHD1 restriction and dNTP hydrolysis.
Phosphorylation disassembles the SAMHD1 tetramer to down regulate
triphosphohydrolase activity
Phosphorylation by CDK2/cyclin A or substitution of T592 with phosphomimetic residues has
been shown to prevent HIV-1 restriction by SAMHD1 in cycling and differentiated cells
respectively. However, how this affects enzyme activity and dNTP levels is uncertain [19, 22,
26]. Our data show that in differentiated U937 cells, alanine substitution at T592 had only a
small effect on restriction but that phosphomimetic substitution by aspartate and glutamate
completely eliminated the ability of SAMHD1 to restrict (Fig 6A). However, in contrast to
Cribier et al. [19], preventing phosphorylation in cycling U937 cells, by, in our case introducing
a T592A alanine mutation, did not rescue SAMHD1 restriction (Fig 6B), suggesting that under
these circumstances, inhibiting phosphorylation is insufficient to gain restriction.
Given the requirement of the (584–626) CtD region of SAMHD1 for stable tetramer forma-
tion in vitro and the effects of phosphomimetic and alanine mutations on restriction, the con-
tribution of CDK2/cyclin A phosphorylation on SAMHD1 tetramerisation, and
triphosphohydrolase activity were investigated in vitro. For these studies SAMHD1 (115–626)
was first in vitro phosphorylated by incubation with CDK2/cyclin A kinase. After treatment,
analysis by tryptic digest and tandem mass-spectrometry found only a single site of phosphory-
lation at T592 (S7A Fig). In addition, the proportion of phosphorylation was assessed using
Phos-tag SDS-PAGE showing that only a single new species was produced and that greater
than 90% of the SAMHD1 was modified (S7B Fig) demonstrating that specific and near stoi-
chiometric phosphorylation of SAMHD1(115–626) at T592 was attained.
The capacity for phospho (p) SAMHD1(115–626) to tetramerise upon addition of GTP and
dATP was then assessed using SEC-MALLS. These data (Fig 6C) show that phosphorylation
also resulted in the inhibition of stable tetramer formation, similar to that observed with
SAMHD1(115–583) and the dimer interface mutant R372D. Given these observations, we
determined the crystal structure of pSAMHD1(115–626). The structure (Fig 6D) is also tetra-
meric with the same dimer of dimers conformation mediated by α13 interactions observed in
the SAMHD1(115–583) and SAMHD1(41–583) structures. GTP and dATP were included in
the crystallisation condition and GTP occupies AL1 but the active site is empty, likely because
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of hydrolysis of the dATP. Similar to that observed in the SAMHD1(115–583) tetramer in one
of the dimer-dimer interfaces, only the first three N-terminal turns of α13 are in close proxim-
ity resulting in a tetramer with an asymmetric arrangement. A structural alignment of
pSAMHD1(115–626) and SAMHD1(115–583) tetramers also reveals that although the confor-
mation of dimers are near identical (0.58 Å rmsd of all Cα) a small displacement in the posi-
tioning of α13-helices (~3 Å) results in a different rotation of one dimer with respect to other
between the two tetramers (Fig 6E). The observation of a further alternative dimer-dimer con-
formation adopted in pSAMHD1(115–626) tetramer strengthens the notion of a conforma-
tional plasticity within the dimer-dimer-interfaces of SAMHD1 tetramers.
Although the pSAMHD1(115–626) tetramer includes the CtD region containing the T592
phosphorylation site, no density is observed for residues C-terminal to D583 suggesting that
this region of the protein becomes disordered upon phosphorylation. In addition, the
pSAMHD1(115–626) structure is much more “open” than the structures of unphosphorylated
“closed” tetramers [13, 14] where residues 582–595 comprise a short CtD helix-turn-helix
motif (CtD-HTH). In these closed structures residues Q582 and D585, located in the first helix
(582–588) of the motif, make hydrogen bonds with R528 and Q536 in the β7-β8 loop region of
an opposing SAMHD1 dimer and provide further tetramer-stabilising interactions additional
to the α13-α13 interface. T592 is located on the second helix (591–595) where its hydroxyl side
chain is hydrogen bonded to the sidechain of D585 as part of the network of interactions that
both stabilise and align the helix-turn-helix motif with the opposing β7-β8 loop. In the
pSAMHD1(115–626) tetramer, residues C-terminal to D583 are disordered, the CtD-HTH is
not formed and so these additional tetramer stabilising interactions do not occur. Moreover,
modelling of phosphorylation of T592 into closed structures introduces substantial clashes of
the phosphate group with residues in the CtD-HTH, especially with the sidechains of D585
and P593. This gives rise to the notion that T592 phospho-dependent disruption/disordering
of the CtD-HTH results in the loss of the additional tetramer stabilising interactions with the
β7-β8 loop and that it is these interactions that are required for stable tetramer formation
observed by SEC-MALLS.
To examine how phosphorylation affects SAMHD1 triphosphohydrolase activity we ini-
tially employed steady-state kinetics to compare the activity of SAMHD1(115–626) and
pSAMHD1(115–626). Surprisingly, these data (Fig 7A) revealed that both phospho- and non-
phospho forms have comparable kcat and Km for TTP hydrolysis. However, these experiments
were conducted under steady-state conditions at “high” substrate and activator concentration.
Therefore, in order to better understand how phosphorylation and tetramer disassembly might
regulate restriction, an activator-depletion coupled to an “advantageous” substrate experiment
was carried out. Here, SAMHD1(115–626) and pSAMHD1(115–626) were first incubated with
GTP and dATP until all substrate dATP was depleted (Fig 7B). Then ddGTP was added and
hydrolysis assessed by IEX-HPLC, Fig 7C. ddGTP cannot induce tetramer formation alone
Fig 6. The effect of phosphorylation on SAMHD1 restriction and tetramerisation.Restriction of HIV-1 infection by SAMHD1 Thr592 mutants in (A)
differentiated and (B) cycling U937 cells. Cells were transduced with the indicated SAMHD1 phosphomimetic mutants, differentiated (A only), infected and
analysed as in Fig 1. Bar charts show the fold restriction. Error bars represent standard deviation of the mean, (n = 6) for A and (n = 3) for B. (C) SEC-MALLS
analysis of wild type SAMHD1(115–626) (black) and phospho-SAMHD1(115–626) (blue) incubated with 0.1 mMGTP and 0.5 mM dATP. The
chromatograms are the output from the differential refractometer. The red points are the weight-averaged molar masses determined for the two peaks in the
wild type protein. (D) Crystal structure of pSAMHD1(115–626) tetramer. Individual monomers are coloured cyan, green, magenta and orange. Active site
bound Fe metal ions are shown as spheres. (E) Structural alignment of pSAMHD1(115–626) (cyan and magenta) and SAMHD1(115–583) (grey) tetramers.
For clarity only two SAMHD1 monomers from each structure, comprising one dimer-dimer interface are shown. The structures were aligned on the upper
dimer (cyan onto grey) to demonstrate the small displacement in the pSAMHD1(115–626) dimer-dimer interface with respect to that of the SAMHD1(115–
583) structure (magenta onto grey). The α13 helix-pairs at the dimer-dimer interfaces are indicated by the double-arrows (left) SAMHD1(115–583) and (right)
pSAMHD1(115–626). The active site Fe and ddGTP in SAMHD1(115–583) are also shown in sphere and in stick representation respectively.
doi:10.1371/journal.ppat.1005194.g006
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(S3A Fig) but unlike other ddNTP substrates can be hydrolysed when other dNTP activators
occupy AL2 (S8 Fig). Fig 7C shows that whilst SAMHD1(115–626) readily hydrolyses the
newly added substrate pSAMHD1(115–626) is unable to hydrolyse the ddGTP. These data sug-
gest that the capacity to form a stable tetramer allows dNTPs to be retained in the allosteric
sites, maintaining the active form of SAMHD1 even when dNTPs are at very low levels. In con-
trast, phosphorylation of SAMHD1 destabilises tetramer formation resulting in the loss of acti-
vating dNTPs and down-regulation of pSAMHD1 activity in a depleted deoxynucleotide
environment.
Discussion
SAMHD1 triphosphohydrolase activity and restriction
It was the triphosphohydrolase activity of SAMHD1 that was first described to be responsible
for restriction of HIV-1 [7, 15]. However, more recently, it has been reported that SAMHD1
has nuclease activity and that this putative RNase activity is its key antiviral property [20, 23].
In addition, there are disputes over which domains of SAMHD1 are required for restriction.
Here, we demonstrate that both the HD domain and CtD are required for restriction of HIV-1
in differentiated U937 cells expressing SAMHD1, but that the SAM domain and N-terminal
region containing the NLS are dispensable (Fig 1). In contrast to a recent report [20], the pres-
ence of the SAM domain does not enhance the magnitude or significantly alter the kinetics of
restriction (Fig 1). At the active site, Fe as well as other metals, including Zn, can be co-ordi-
nated (S5 Fig). However, the metal-type affects the configuration of the bound nucleotide (Fig
3C) and Zn actually inhibits triphosphohydrolase activity (S5D Fig), suggesting that differential
metal binding at the SAMHD1 active site may have a regulatory function. The importance of
nucleotide configuration and metal binding for restriction is also apparent as mutations made
at both metal-coordinating residues and those required for nucleotide binding all result in a
loss of restriction activity (Fig 5). At the allosteric site, all G-based nucleotides are accommo-
dated and support SAMHD1 triphosphohydrolase activity. Mutation of the AL1 G-recognition
residue R145 to alanine or introduction of the AGS mutation R143C that makes hydrogen
bonds to both R145 in AL1 and H210 in the active site also both abolish restriction (Fig 5).
These data suggest that both binding of the G-based nucleotide in AL1 and the linkage of active
and allosteric sites through the R143 “bridge” are requirements for restriction.
These results indicate that inhibition of HIV-1 by SAMHD1 requires the enzyme to be com-
petent for binding both dNTPs and metal ions in the active site and dNTPs at the allosteric site
strongly suggesting that restriction is linked to the capacity of SAMHD1 to hydrolyse dNTPs.
Further, our data show that HIV-1 with reverse transcriptase (RT) mutations that result in a
less processive enzyme or increased KM for deoxynucleotide substrates [27–29] are more sensi-
tive to SAMHD1 (Fig 1E). As these mutants have the same genomic RNA they would be
expected to have the same sensitivity to an RNase activity, and so these data further support
Fig 7. The effect of phosphorylation on SAMHD1 enzyme activity. (A) Steady-state kinetic analysis of
GTP stimulated hydrolysis of TTP, by SAMHD1 (115–626) (black) and phospho-SAMHD1(115–626) (blue).
The dependence of the rate of on substrate concentration is plotted. Error bars represent SEM of three
independent measurements. Solid lines are the best fit to the data using the Michaelis-Menten expression.
The derived constants KM and kcat are shown inset. (B and C) Effect of activator depletion on SAMHD1 and
pSAMHD1 triphosphohydrolase activity. (B) IEX-HPLC analysis of nucleotide composition after incubation of
SAMHD1(115–626) with GTP (upper), and pSAMHD1(115–626) (middle) or SAMHD1(115–626) (lower) with
dATP and GTP for 0 and 300 seconds. (C) IEX-HPLC analysis of the hydrolysis of ddGTP added to the
samples depleted of dATP in (B). The plot shows the quantification of the time dependent hydrolysis derived
from integration of the ddGTP peak at each time point. Error bars represent the SEM from 3 independent
experiments.
doi:10.1371/journal.ppat.1005194.g007
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the notion that the SAMHD1 triphosphohydrolase activity limits dNTP availability for RT and
that this inhibits viral infection at the time of reverse transcription.
Regulation of triphosphohydrolase activity and restriction through
tetramerisation and phosphorylation
Our data show that the CtD of SAMHD1 is required for restriction activity (Fig 1). Deletion of
the CtD abolishes stable tetramer formation in vitro (Fig 2A), although transient tetramers pre-
sumably can form as the crystal structures of SAMHD1(1–583) and SAMHD1(41–583) are tet-
rameric (Fig 3A). Preventing any tetramer formation by mutation of R372, a key residue in the
primary α13-α13 tetramer interface, also blocks restriction and severely impairs triphosphohy-
drolase activity (Fig 5). These data strongly suggest that, in addition to nucleotide binding and
hydrolysis, SAMHD1 stable-tetramerisation is also required for restriction. However, although
removal of the CtD reduces triphosphohydrolase activity in vitro, by around 10-fold, it is not
completely abolished, and the Km for substrates is not strongly affected (Fig 2D), indicating
that stable tetramerisation is not a mechanistic requirement for catalysis. These data are sup-
ported by the observation that the amount of stable tetramer formed is highly dependent on
the identity of the nucleotide occupying AL2 (S3B Fig) but regardless, all dNTPs are still hydro-
lysed at a comparable rate [30]. Again, this suggests that stable tetramerisation is not an abso-
lute requirement for in vitro SAMHD1 triphosphohydrolase activity making its role in
restriction unexplained.
Recent studies have identified phosphorylation as a means to regulate SAMHD1 activity in
cells [19, 22, 26]. However, the mechanism of regulation is unclear, as phosphomimetic
mutants display no apparent triphosphohydrolase defect in vivo [22, 26]. Moreover, in the
reported structures of non-phosphorylated SAMHD1 tetramers [13, 14], the phosphorylation
site was remote to both the active and allosteric site of the enzyme. These observations fur-
thered suggestions that SAMHD1 has an alternative activity to dNTP hydrolysis and/or
required a co-factor in cells, in order to restrict retroviral replication [22, 26]. Given the degree
of conformational flexibility we observe at the tetramer interface (Figs 3 and 6) combined with
our in vitro tetramerisation data, we questioned whether phosphorylation might regulate tetra-
mer formation. We found that introduction of phosphomimetic mutants at T592 abolishes
restriction activity in cells and that phosphorylation of residue T592 in vitro inhibits stable tet-
ramer formation (Fig 6C). Moreover, the structure of pSAMHD1 (115–626) has an open con-
formation highly similar to that of the C-terminally deleted SAMHD1 structures. However,
steady-state kinetic measurements of pSAMHD1 revealed that although T592 phosphorylation
prevents stable tetramer formation and blocks restriction, it has surprisingly little effect on
SAMHD1 dNTP turnover in vitro (Fig 7A). This could suggest that triphosphohydrolase activ-
ity is not linked to restriction and that tetramerisation is required for an alternative mecha-
nism. SAMHD1 oligomers including tetramers have been observed in cells [21, 25]. However,
as the putative RNase activity does not require tetramerisation [23], and our other require-
ments for restriction are all linked to dNTP binding, this seems unlikely.
Our experiments in vitro were performed under steady state conditions that are likely very
different to those in non-dividing differentiated myeloid cells and resting T-cells that have low
dNTP levels [6, 15–17, 33]. Therefore, we assessed how SAMHD1 activity was affected under
conditions of activator-depletion (Fig 7B and 7C) where the enzyme response to the environ-
ment may be more important than the steady-state rate of catalysis. By using a ddGTP sub-
strate that is hydrolysed only when a dNTP fills AL2 we were able to separate substrate from
activator function (Fig 7C). These data reveal that the inability of pSAMHD1 to form a stable
tetramer results in a molecule that is catalytically competent at high nucleotide/activator levels
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(Fig 7A) but that is unable to hydrolyse substrate at low activator (dNTP) levels (Fig 7C). We
therefore conclude that the CtD of SAMHD1 is required to stabilise the tetrameric, active form
of the protein by holding it in a closed, tight tetramer form. Phosphorylation of T592 disrupts
the CtD, allowing transient, open active tetramers to form but preventing the stabilisation of
these tetramers. Removing the CtD also prevents stable tetramer formation and has a more
severe effect on the enzyme kinetics. Disruption of the primary α13-α13 dimer-dimer interface
has the most severe effect and leads to inability to tetramerise and abolishes triphosphohydro-
lase activity. Notably, none of our deletion or phosphomimetic SAMHD1 mutants restricted
HIV-1 replication in cycling U937 cells (Figs 1C and 6B). Cribier et al. reported that a 576–626
SAMHD1 deletion that removes the phosphorylation site enables SAMHD1 to restrict HIV-1
in cycling cells [19]. However, as well as preventing phosphorylation, we would predict that a
576–626 deletion should prevent SAMHD1 stable tetramerisation as observed with our 583–
626 CtD mutant (Fig 2A) and therefore would only be functional at high dNTP levels that do
not restrict HIV-1 replication.
Given all these observations, a unifying model for SAMHD1 restriction of HIV-1, can be
proposed, Fig 8. Here, we postulate that in the differentiated cellular environment depleted of
activating dNTPs, only SAMHD1 variants that can form long-lived, stable tetramers are func-
tionally active due to their ability to retain activating nucleotides in the allosteric site [31].
These stable tetramers are necessary and sufficient for restriction of retroviral replication
because they can reduce and maintain the dNTP pool to very low levels below the threshold
that HIV requires for reverse transcription. By contrast, in cycling cells, dNTP levels are gener-
ally higher because of dNTP synthesis through ribonucleotide reductase activity. In these cells,
transient pSAMHD1 tetramers can still hydrolyse dNTPs, but as the pool depletes, activating
nucleotides can be lost from AL2 and so the enzyme dissociates to inactive dimers and the
dNTP pool is never reduced to very low levels. Such low dNTP levels are difficult to accurately
measure against background noise in most assays, possibly contributing to conflicting reports
in the field. Improved understanding of the mechanism of SAMHD1 activity and its regulation
is crucial as, in addition to inhibiting exogenous, and potentially endogenous, viral replication
SAMHD1 is an important regulator of intracellular dNTP levels [34]. Our findings therefore
have wide-ranging implications in these fields and may also inform the mechanistic pathogene-
sis of AGS.
Methods
SAMHD1 Plasmids and expression
For SAMHD1-YFP expression plasmids, a full-length codon-optimised SAMHD1 sequence
was amplified from pLgatewaySN_SAMHD1 [7], sub-cloned into pENTR/D/TOPO using the
pENTR Directional Cloning Kit and transferred into pLgatewayIRESEYFP using Gateway LR
Clonase II Enzyme mix (Invitrogen). Mutants A, B, D, F and I were amplified from pLgate-
way_SAMHD1IRESYFP using primers listed in the S1 Table. PCR reactions contained 0.5 μM
forward and reverse primers, 200 μM dNTP, 1X Phusion HF buffer, 10 ng template and 1 Unit
Phusion High-Fidelity DNA Polymerase (NEB). Cycling conditions consisted of initial dena-
turation at 98°C for 30 sec, 98°C for 10 sec, 70°C for 30 sec, 72°C for 1 min (for 35 cycles) and
final extension of 10 min at 72°C. Inserts were cloned into pLgatewayIRESEYFP as above.
Mutants C, G and H were made using Quikchange II Site-directed Mutagenesis Kit (Strata-
gene) according to the manufacturer’s instructions using pLGateway_SAMHD1IRESYFP as
a template for G and H, F for C, H for E and the primers listed in the S1 Table. For puromycin
resistance vectors, full-length SAMHD1 and mutant F were amplified from pLgateway
SN_SAMHD1, using primers listed in the S1 Table, and cloned into pCMS28 [35] using
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restriction digest with XhoI and EcoRI or HpaI, and ligation. Mutant H was created from
pCMS28_SAMHD1 as above. Point mutations were created in full-length pLgateway_SAMH-
D1IRESYFP and Reverse Transcriptase mutations were created in p8.91 [36] using the Quik-
change II Site-directed Mutagenesis Kit (Agilent technologies). RT mutant 114S was a gift
from S. Okura. SAMHD1 expression in transduced cells was analysed by immunoblotting
using 1/500 anti-SAMHD1 3295 (in house) followed by 1/5000 anti-rabbit IRDYE800 (Tebu
Bio), and imaged on an Odyssey Infrared Imager (Licor).
Cells and virus production
293T and TE671 cells were maintained in DMEM (Invitrogen) and U937 cells in RPMI +[L]-
Glutamine (GIBCO), each supplemented with 10% heat inactivated foetal calf serum (Biosera)
Fig 8. Model for phospho-regulation of SAMHD1 restriction. In the absence of dNTPs Apo-SAMHD1 is found in a monomer-dimer equilibrium regardless
of the phosphorylation state (1). At high dNTP levels, typically in cycling cells, constitutively abundant GTP combines with dNTPs to fill allosteric sites. In both
phosphorylated and un-phosphorylated SAMHD1 this results in the formation of an activated tetramer (2) that in the non-phosphorylated protein also
includes additional intra-tetramer CtD interactions forming a stable activated tetramer (3). Under these conditions, both activated and stable activated
tetramers hydrolyse the dNTP pool at comparable rates. At lower dNTP levels, the stabilisation afforded by the CtD interactions maintains enzyme activity in
non-phosphorylated SAMHD1 by preventing the loss of dNTP-activator from the allosteric site. However, in phospho-SAMHD1, activating dNTPs dissociate
from the allosteric site (4) resulting in disassembly of the tetramer and down-regulation of triphosphohydrolase activity. At very low levels, such as in
differentiated myeloid cells, CtD-stabilised tetramers still retain activating dNTPs in the allosteric site (5) and SAMHD1 remains catalytically competent. It can
therefore rapidly respond to any increase in intracellular dNTPs to maintain the dNTP levels below the threshold required for HIV-1 replication.
doi:10.1371/journal.ppat.1005194.g008
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and 1% penicillin/streptomycin (Sigma). U937 cells stably expressing SAMHD1 variants were
prepared by transduction with MoMLV-based Puromycin-expressing VLPs, followed by selec-
tion with puromycin at 10 μg/mL. MoMLV-based YFP-expressing VLPs were made by
cotransfecting 293T cells with pVSV-G (gifted from D. Lindemann), pKB4 [37] and pLGate-
way_SAMHD1IRESYFP (wild-type or mutants), harvesting 48 hr post-transfection. HIV-
1GFP was produced by cotransfection of pVSV-G, p8.91 and pCSGW [38]. MoMLV-based
Puromycin-expressing VLPs were made by cotransfection of pKB4, pVSV-G and
pCMS28_SAMHD1 (wild-type or mutants). VLPs were titred on TE671 or 293T cells for nor-
malisation prior to infection. Viruses with mutations in Reverse Transcriptase were normalised
by HIV-1 p24 ELISA (Perkin Elmer).
Two-colour flow cytometry
U937 cells (1 x 106) were transduced by spinoculation in a 24 well plate at 1,700 rpm (Sorvall
Legend RT 75006441L) for 90 min with 0.5 mL normalised virus in the presence of 10 μg/mL
polybrene (to give approximately 30% transduction). Cells were transferred to a 6 well plate
and 1.5 mL RPMI added. 3 days later, cells were passaged 1/3, differentiated with 100 nM Phor-
bol 12-myristate 13-acetate (PMA, Sigma) for 72 hours and then infected with HIV-1GFP
(~10 ng CA) in fresh media. For experiments using cycling cells, the differentiation step was
omitted. Restriction was assessed after 72 hours by 2-colour flow cytometry using BD LSR II or
BDVERSE flow cytometers using single colour controls and automatic compensation [39].
Restriction was calculated by dividing the percentage of transduced (YFP +ve) cells that were
infected (GFP +ve) by the percentage of non-transduced cells that were infected. Positive
(wild-type SAMHD1) and negative (HD206-7AA catalytic site mutant) controls were included
for each experiment. Statistical differences between wild type and mutants were determined
using the Mann-Whitney test (Dunn’s multiple comparisons test for reverse transcriptase
mutants).
Quantification of reverse transcription products
U937 cells (4 x 106) were transduced by spinoculation at 1,700 rpm (Sorvall Legend RT
75006441L) for 90 min with 0.5 mL concentrated virus in the presence of 1 μg/mL polybrene
(to give>80% transduction). 3 days later, cells were plated at 3.8 x 106 cells per well of a 12
well plate in the presence of 100 nM PMA. After 72 hours cells were chilled at 4°C for 30 min
and infected with DNase-treated HIV-GFP (10 ng CA) at 4°C for 30 min and transferred to
37°C (time 0). Cells were harvested at the indicated times post-infection by removing media,
washing with ice-cold PBS, trypsinising, resuspending in ice-cold PBS, pelleting at 2000 xg for
2 min at 4°C and flash-freezing on dry ice. DNA was isolated using the DNeasy Blood & Tissue
Kit (Qiagen). Eluted DNA was treated with DpnI for 1 hour and quantitation of strong stop
and second strand PCR products was determined by qPCR using the primers detailed in S2
Table. PCR reactions contained 9 μM forward and reverse primers, 2.5 μM probe, 1X Taqman
Fast Advanced Mastermix and 2 μL DNA. Reactions were carried out in a 7500 Fast Real-Time
PCR System (Applied Biosystems) using standard reaction conditions.
Measurement of deoxynucleoside triphosphate levels in cells
Cellular deoxynucleoside triphosphates were extracted from batches of 4x106 differentiated
native and SAMHD1 transduced U937 cells according to [40]. The dNTP levels were quanti-
fied by radiolabel incorporation assays performed using oligonucleotide templates detailed in
[41] and the procedures described in [42] with the following modifications. Standard curves
ranged from 0.05 to 4 pmole, 1 unit of KOD polymerase (Merck Millipore) was used in place
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of Thermo-Sequenase (GE Healthcare) and 2.5 μM of α-32P-dATP was employed as an incor-
poration label.
Protein expression and purification
For expression in E. coli the DNA sequences coding for human SAMHD1 residues M1-M626,
M115-M626, P26-M626, M115-D583 and D41-D583 were amplified by PCR and inserted into
a pET52b expression vector (Novagen) using ligation independent cloning to produce N-ter-
minal StrepII-tag fusion proteins. The M115-D583 (R164A) and M1-M626 (R372D) mutants
were prepared from the parent construct using the Quikchange II kit. All insert sequences were
verified by DNA sequencing. Strep-tagged SAMHD1 constructs were expressed in the E. coli
strain Rosetta 2 (DE3) grown in Luria broth at 37°C with shaking. Protein expression was
induced by addition of 0.1 mM IPTG to log phase cultures (A600 = 0.5) and the cells incubated
for a further 20 h at 18°C. Cells were harvested by centrifugation resuspended in 30 ml lysis
buffer (50 mM Tris-HCl pH 7.8, 500 mMNaCl, 4 mMMgCl2, 0.5 mM TCEP, 1x EDTA-free
mini complete protease inhibitors (Roche), 0.1 U/ml Benzonase (Novagen) per pellet of 1 L
bacterial culture and lysed by disruption in EmulsiFlex-C5 homogeniser (Avestin). The lysate
was cleared by centrifugation for 1 h at 48,000 xg and 4°C then applied to a 10 mL StrepTactin
affinity column (IBA) followed by 600 mL of wash buffer (50 mM Tris-HCl pH 7.8, 500 mM
NaCl, 4 mMMgCl2, 0.5 mM TCEP) at 4°C. Bound proteins were eluted from the column by
circulation of 1 mg of 3C protease (GE) in 10 mL of wash buffer over the column in a closed
circuit overnight. 3C protease was removed by incubation of the eluent with 500 μL GSH-Se-
pharose (GE). After centrifugation to remove the resin, the supernatant was concentrated to
5 mL and applied to Superdex 200 16/60 (GE) size exclusion column equilibrated with 10 mM
Tris-HCl pH 7.8, 150 mMNaCl, 4 mMMgCl2, 0.5 mM TCEP. Peak fractions were concen-
trated to approximately 20 mg/mL and flash-frozen in liquid nitrogen in small aliquots.
Crystallisation and structure determination
Prior to crystallisation, protein samples were diluted to 5 mg/mL with gel filtration buffer, sup-
plemented with 1 mM of the appropriate nucleotide (Jena Bioscience). Crystals were produced
by hanging drop vapour diffusion at 18°C using an Oryx crystallisation robot (Douglas instru-
ments) and 2 μL droplets containing an equal volume of the protein/nucleotide solution and
mother liquor.
Crystals of SAMHD1(41–583)-ddGTP were obtained from hanging drops containing
160 mM succinic acid, 11% PEG 3350, pH 7.0. Crystals of SAMHD1(115–583)-ddGTP were
obtained from drops containing 100 mM Bis Tris propane-HCl, 150 mMNa2SO4, 13.5% PEG
3350 pH 6.5. Crystals of SAMHD1 115–583 R164A-dGTP were obtained from drops contain-
ing 0.2 M sodium citrate, 0.1 M Bis Tris propane-HCl, 20% PEG 3350, pH 8.5 and Crystals of
SAMHD1(115-626-d4T/GTP) were obtained from drops containing 0.2 M ammonium sul-
phate and 20% PEG 3350. Crystals of pSAMHD1(115–626) were obtained from drops contain-
ing 0.2 M sodium formate and 20% PEG 3350 with 25 mM dATP and GTP included in the
crystallisation condition. Details of crystallographic spacegroups, cell dimensions and contents
of the asymmetric unit are presented in Table 1.
For data collection, crystals were adjusted to 25% glycerol and flash frozen in liquid nitro-
gen. Datasets were collected on beamline I04 at the Diamond Light Source, UK at a wavelength
of 0.97949 Å or 0.92 Å with the exception of the SAMHD1 115-583-ddGTP dataset, which was
collected at a wavelength of 1.735 Å, corresponding to the Fe absorption edge. Data were
reduced using the HKL [43] or XDS [44, 45] software suites. Structures were solved by
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molecular replacement using the programMOLREP [46] implemented in the CCP4 interface
[47] using the structure of apo-SAMHD1 120–626 as search model (PDB code 3U1N, [7]).
For the SAMHD1(115–583) crystal, iterative model building with the program Coot [48]
combined with positional, real-space, individual B-factor and TLS refinement in phenix.refine
[49] produced a final model for SAMHD1 residues 115–276, 282–530, 538–583 (chain A);
115–277, 282–506, 513–530, 547–583 (chain B); 115–276, 284–532, 538–583 (chain C); 115–
276, 284–506, 512–530, 547–582 (chain D) with R-/Rfree-factors of 16.49%/22.28%. In the
model, 97.98% of residues have backbone dihedral angles in the favoured region of the Rama-
chandran plot, a further 1.74% are in the allowed regions and 0.28% are outliers.
For the SAMHD1(41–583) crystal, iterative model building with Coot combined with posi-
tional, real-space, grouped B-factor, TLS refinement and inclusion of reference restraints from
the higher-resolution SAMHD1 115–583 model in phenix.refine produced a final model for
SAMHD1 residues 110–276, 285–505, 517–531, 547–582 (chain A); 113–277, 287–463, 466–
506, 517–529, 548–583 (chain B) with R-/Rfree-factors of 20.94%/26.71%. In the model,
98.48% of residues have backbone dihedral angles in the favoured region of the Ramachandran
plot, 1.28% fall in the allowed regions and 0.23% are outliers.
For the SAMHD1(115–583)-R164A crystal, iterative model building with Coot combined
with positional, real-space, individual B-factor and TLS refinement produced a final model for
SAMHD1 residues 115–276, 284–505, 515–530, 547–582 (chain A); 115–276, 285–505, 547–
582 (chain B); 115–276, 283–483, 490–507, 514–530, 539–542, 547–582 (chain C); 115–276,
285–505, 547–582 (chain D) with R-/Rfree-factors of 15.62/23.44. In the model, 97.8% of resi-
dues have backbone dihedral angles in the favoured region of the Ramachandran plot, 1.79%
are in the allowed regions and 0.42% are outliers.
For the SAMHD1(115–626 crystal), iterative model building with Coot combined with posi-
tional, real-space, grouped B-factor and TLS refinement produced a final model for SAMHD1
residues 115–276, 285–507, 513–530, 547–583 (chain A); 115–276, 285–506, 514–530, 547–
583 (chain B); 115–276, 284–506, 515–530, 547–583 (chain C); 115–276, 284–505, 514–530,
547–583 (chain D) with R-/Rfree-factors of 17.71/24.73. In the model, 97.9% of residues have
backbone dihedral angles in the favoured region of the Ramachandran plot, 1.97% are in the
allowed regions and 0.12% are outliers.
For the pSAMHD1(115–626) crystal, iterative model building with Coot combined with
positional, real-space, grouped B-factor and TLS refinement in phenix.refine produced a final
model for SAMHD1 residues 115–276, 285–505, 517–526, 547–583 (chain A), 115–276, 285–
463, 468–484, 491–505, 516–529, 547–581 (chain B), 115–276, 284–394, 407–460, 468–479,
496–505, 518–522, 547–580 (chain C), 117–273, 286–303, 308–460, 474–484, 500–505, 518–
529, 549–553, 560–581 (chain D) with R-/Rfree-factors of 24.39/30.82. In the model, 96% of
residues have backbone dihedral angles in the favoured region of the Ramachandran plot, 4%
are in the allowed regions and 0% are outliers.
Structural alignment and superposition was undertaken using SSM [50] and LSQMAN
[51]. Protein structure figures were prepared using PYMOL [52]. The coordinates and struc-
ture factors of SAMHD1(41–583)-ddGTP SAMHD1(115–583)-ddGTP, SAMHD(115–583)-
R164A-dGTP, SAMHD1(115–626)-d4T-GTP and pSAMHD1(115–626)-GTP have been
deposited in the Protein Data Bank under accession numbers 5ao0, 5ao1, 5ao2, 5ao3 and 5ao4
respectively.
SEC-MALLS
Size Exclusion Chromatography coupled to Multi-Angle Laser Light Scattering (SEC-MALLS)
was used to determine the molar mass composition of SAMHD1 samples upon addition of
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deoxynucleotide/nucleotide substrates and activators. For the time course assessing tetramer
stability, samples were incubated at 4°C for the specified time after the addition of nucleotide
substrates and activators. Samples (100 μl) were applied to a Superdex 200 10/300 GL column
equilibrated in 20 mM Tris-HCl, 150 mMNaCl, 5 mMMgCl2, 0.5 mM TCEP and 3 mM
NaN3, pH 8.0, at a flow rate of 0.5 ml/min. The scattered light intensity and protein concentra-
tion of the column eluate were recorded using a DAWN-HELEOS II laser photometer and an
OPTILAB-TrEX differential refractometer (dRI) (dn/dc = 0.186) respectively. The weight-aver-
aged molecular mass of material contained in chromatographic peaks was determined using
the combined data from both detectors in the ASTRA software version 6.1 (Wyatt Technology
Corp., Santa Barbara, CA).
ICP-MS
Inductively coupled plasma mass spectrometry (ICP-MS) was employed to determine the iden-
tity of the metal ions bound by SAMHD1. Samples were prepared for ICP-MS by extensive
dialysis against 20 mM Tris pH 8.0, 150 mMNaCl, 5 mMMgCl2 and 2 mM TCEP and the
final protein concentration adjusted to 20 μM. Samples (100 μl) were then added to 3 mL of 2%
HNO3 and quantitative transition metal analysis carried out using an Agilent 7500cx Induc-
tively Coupled Plasma Mass Spectrometer (Manchester Analytical Geochemistry Unit, Univer-
sity of Manchester). External calibration was accomplished using standards with
concentrations of 5, 10, 50, 100 and 200 μg/L. Calibration standards were prepared immedi-
ately prior to analysis by dilution of concentrated multi-element stock solutions with 2% sub-
distilled HNO3 in 18 MO deionised water.
IEX-HPLC assay of SAMHD1 triphosphohydrolase activity
3 μM SAMHD1 was incubated with 0.2 mM GTP activator and 0.5 mM dATP substrate in
either Reaction buffer, 20mM Tris-HCl, 150 mMNaCl, 5 mMMgCl2, 2 mM TCEP (pH 7.5) or
Reaction buffer including 10 μMZnSO4. Reactions were allowed to proceed and samples with-
drawn at timed intervals up to 3 minutes and terminated by 10 fold dilution into 18.0% aceto-
nitrile, 25mM Tris-HCl, 1 mM EDTA pH 8.0. For assessment of SAMHD1 hydrolysis of
ddNTP substrates 3 μM SAMHD1 was incubated with 0.2 mM GTP/dATP activators together
with 1 mM ddNTP substrates. In activator-depletion experiments 3 μM SAMHD1(115–626)
or pSAMHD1(115–626) was first incubated with 0.05 mM GTP activator and 0.2 mM dATP
in Reaction buffer until all substrate dATP was depleted (5 minutes). After the depletion phase
0.5 mM ddGTP was added and samples of the time-course of hydrolysis withdrawn and termi-
nated as above. The nucleotide hydrolysis reactions were analysed by anion exchange HPLC
using a DNA-PAC100 (4 x 50mm) column (Dionex). The column was equilibrated at 30°C at
1 mL/min in 25mM Tris-HCl, 0.5% acetonitrile pH 8.0 (Buffer A). Samples of the reaction
(2 nmole) were eluted with a five-minute isocratic phase of Buffer A followed by linear gradient
of 0 to 240 mMNH4Cl over 12 minutes. Absorbance data from the column eluent was continu-
ously monitored between 200-400nm (2 nm interval) using MD-2010 photodiode array detec-
tor (JASCO). Peak integration of the absorbance data recorded at 260 nm was used to quantify
the amount of substrate and products at each time point of the reaction.
Real time measurement of triphosphohydrolase activity
To obtain quantitative, time-resolved information and kinetic parameters for SAMHD1 nucle-
otide hydrolysis, a coupled assay was employed utilising the biosensor MDCC-PBP [53, 54] to
measure phosphate release from combined SAMHD1 triphosphohydrolase and S. cerevisiae
Ppx1 exopolyphosphatase activity in real time, as described previously [32]. In a typical
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experiment, solutions containing SAMHD1 constructs, Ppx1, MDCC-PBP and GTP were
incubated for 5 min in assay buffer (20 mM Tris pH 8.0, 150 mMNaCl, 5 mMMgCl2 and
2 mM TCEP) at 25°C before the reaction was initiated by the addition of substrate (TTP). The
final concentrations were 100 nM SAMHD1, 10 nM Ppx1, 40 μMMDCC-PBP, 0.2 mM GTP
and varying concentration of TTP. The fluorescence intensity was recorded at 430 nm excita-
tion and 465 nm emission over a period of 10–30 min in a Clariostar multiwall plate reader
(BMG). Steady state rates were obtained from time courses of Pi formation by linear regression
of the data points in the linear phase of the reaction. Rates were divided by the SAMHD1 con-
centration and plotted versus substrate concentration. Apparent dissociation constants for sub-
strate binding (KM) and catalytic constants (kcat) were then determined by nonlinear least
squares fitting using either a hyperbolic or a Hill-function. All measurements were performed
in duplicate or triplicate.
In vitro phosphorylation of SAMHD1
SAMHD1 was in vitro phosphorylated using preassembled human CDK2/cyclin A complex
[55]. In a phosphorylation reaction SAMHD1(115–626) was incubated at a ratio of 75:1 (w/w)
with CDK2/cyclin A in 10 mM Tris-HCl pH 7.8, 150 mMNaCl, 4 mMMgCl2, 0.5 mM TCEP
and 2mM ATP. The reaction was initiated by the addition of SAMHD1(115–626) and incu-
bated for 6 hours at 4°C. The target for phosphorylation was threonine 592 and this was con-
firmed as the sole site of phosphorylation by in-gel trypsin digestion combined with
MALDI-TOF mass spectrometry. The level of phosphorylation was also quantified by applying
pre and post-phosphorylated samples to 6% (w/v) acrylamide SDS PAGE gels supplemented
with 50 μM Phos-tag [56] and Mn2+ (Wako, Japan).
Supporting Information
S1 Fig. Expression of SAMHD1 deletion mutants. U937 cells transduced with SAMHD1
mutant viruses, labelled as in Fig 1A, were harvested at the time of infection with HIV-1GFP
and SAMHD1 protein expression analysed in a 4–20% Tris-glycine gel followed by immuno-
blotting with anti-SAMHD1 antibody. M, marker; un, untransduced U937 cells; FL, full-length
SAMHD1; +, SAMHD1-transfected 293T positive cell control. Marker molecular weights are
indicated. Molecular weights for each mutant were predicted using the primary amino acid
sequence in SeqBuilder (DNAStar) and are shown below along with the percentage YFP posi-
tive cells for each transduction.
(TIF)
S2 Fig. Restriction activity of SAMHD1 deletions in stable cells lines. U937 cells (Parental)
stably expressing either full-length SAMHD1, mutant F or mutant H were differentiated by
adding PMA and 72 hours later infected with HIV-1GFP virus. The percentage of GFP positive
cells was determined by flow cytometry and plotted relative to the amount of HIV-1GFP virus
added to the cells. Error bars represent the range for n7 independent experiments.
(TIF)
S3 Fig. Nucleotide stimulated tetramerisation. (A) SEC-MALLS analysis of monomer-
dimer-tetramer equilibrium for SAMHD1(115–626) upon addition of 0.5 mM GTP (orange),
dGTP (green) and ddGTP (blue). (B) SEC-MALLS analysis of monomer-dimer-tetramer equi-
librium for SAMHD1(115–626) upon addition of 0.2 mM GTP and 0.5 mM each of dATP
(red), dGTP (green), TTP (purple) and dCTP (blue). The chromatograms are the output from
the differential refractometer and the displayed points are the weight-averaged molar masses
determined at 1-second intervals throughout elution of chromatographic peaks. (C) SAMHD1
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triphosphohydrolase activity against ddNTP substrates. GTP/dATP (0.2 mM ea.) stimulated
SAMHD1(115–626) hydrolysis of the indicated ddNTP substrate (1 mM) was analysed by
IEX-HPLC. The plot shows the quantification of the time dependant depletion of substrate
derived from integration of the ddNTP peak at each time point. Error bars represent the SEM
from 3 independent experiments.
(TIF)
S4 Fig. Electron density for dimer-dimer interfaces and active site nucleotides. (A) 2Fo–Fc
electron density for α13 helix dimer-dimer interfaces observed in SAMHD1 tetramer struc-
tures. (Left) Interface I, present in SAMHD1(115–583)-ddGTP, SAMHD1(41–583)-ddGTP
and pSAMHD1(115–626) tetramers. (Right) Interface II, present in SAMHD1(115–583)-
ddGTP tetramer. Electron density, contoured at 1σ, is shown as blue mesh, the protein back-
bone is shown as a ribbon and sidechains in stick representation. (B) 2Fo–Fc electron density
for the active site nucleotides in the SAMHD1(115–583)-ddGTP structure (Left) and
SAMHD1(41–583)-ddGTP structure (Right). Electron density, contoured at 1σ, is shown as
blue mesh, the ddGTP nucleotide and the metal co-ordinating residues shown as sticks, active
site Fe is shown as a sphere (brown) and the protein backbone as a ribbon,
(TIF)
S5 Fig. Active site configuration and identity of bound metal ions. (A) Anomalous-differ-
ence electron density map calculated from diffraction data recorded from a SAMHD1(115–
583)-ddGTP crystal at the Fe absorption edge (1.735 Å). The region around the SAMHD1
(115–583) active site is shown with the difference density, contoured at 5σ, shown as green
mesh. The active site Fe is shown as a sphere (brown), the protein backbone as a ribbon, and
the ddGTP nucleotide and surrounding residues shown as sticks. (B) X-ray fluorescence emis-
sion spectrum of a SAMHD1(115–583) crystal. Excitation energy was 12.66 keV. Peaks corre-
sponding to Fe (Kα 6.40 keV and Kβ 7.06 keV) and Zn (Kα 8.64 keV) emission energies are
observed. A peak at 2.62 keV corresponding to the Kα emission from Cl is also present as the
crystallisation solution contained 150 mM chloride ions. (C) ICP-MS analysis of transition
metal ions contained in SAMHD1. Only Zn and Fe were detected above background. Results
are displayed as the ratio of nmole metal per nmole of protein for each SAMHD1 construct
tested, (n = 1). (D) Zn inhibition of SAMHD1 triphosphohydrolase activity. GTP stimulated
SAMHD1(115–626) hydrolysis of dATP with and without addition of Zn2+ was analysed by
IEX-HPLC. The plot shows the quantification of the time dependant depletion of substrate
derived from integration of the dATP peak at each time point. Error bars represent the SEM
from 3 independent experiments.
(TIF)
S6 Fig. 2Fo–Fc electron density for allosteric site nucleotides. 2Fo–Fc electron density for
allosteric site bound nucleotides in SAMHD1 crystal structures. The structure and associated
bound nucleotide are indicated above. Electron density, contoured at 1σ, is shown as blue mesh
and nucleotides are shown in stick representation.
(TIF)
S7 Fig. In vitro phosphorylation of SAMHD1. (A) ESI-Q-TOF MS/MS fragmentation spec-
trum (m/z range 200 to 2000) the y8 and y16 molecular ions at m/z = 1004.55676 and
900.46710 unambiguously identify the tryptic peptide (N577-K596) and the phosphorylation
at T592. (B) Mn2+ Phos-tag SDS-PAGE analysis of SAMHD1(115–626) pre (Lane 2) and post
(Lane 3) treatment with CDK2/Cyclin A kinase. M, molecular weight markers.
(TIF)
SAMHD1 Phosphorylation, Tetramers and Restriction
PLOS Pathogens | DOI:10.1371/journal.ppat.1005194 October 2, 2015 26 / 30
S8 Fig. ddNTP hydrolysis. SAMHD1 triphosphohydrolase activity against ddNTP substrates.
GTP/dATP (0.2 mM ea.) stimulated SAMHD1(115–626) hydrolysis of the indicated ddNTP
substrate (1 mM) was analysed by IEX-HPLC. The plot shows the quantification of the time
dependant depletion of substrate derived from integration of the ddNTP peak at each time
point. Error bars represent the SEM from 3 independent experiments.
(TIF)
S1 Table. Primers used for SAMHD1 mutant synthesis.
(PDF)
S2 Table. Quantitative-PCR primers.
(PDF)
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